Tissue-Specific Expression Patterns of MicroRNA during Acute Graft-versus-Host Disease in the Rat.
MicroRNAs (miRNA) have emerged as central regulators of diverse biological processes and contribute to driving pathology in several diseases. Acute graft-versus-host disease (aGvHD) represents a major complication after allogeneic hematopoietic stem cell transplantation, caused by alloreactive donor T cells attacking host tissues leading to inflammation and tissue destruction. Changes in miRNA expression patterns occur during aGvHD, and we hypothesized that we could identify miRNA signatures in target tissues of aGvHD that may potentially help understand the underlying molecular pathology of the disease. We utilized a rat model of aGvHD with transplantation of fully MHC-mismatched T cell depleted bone marrow, followed by infusion of donor T cells. The expression pattern of 423 rat miRNAs was investigated in skin, gut, and lung tissues and intestinal T cells with the NanoString hybridization platform, in combination with validation by quantitative PCR. MHC-matched transplanted rats were included as controls. In the skin, upregulation of miR-34b and downregulation of miR-326 was observed, while in the intestines, we detected downregulation of miR-743b and a trend toward downregulation of miR-345-5p. Thus, tissue-specific expression patterns of miRNAs were observed. Neither miR-326 nor miR-743b has previously been associated with aGvHD. Moreover, we identified upregulation of miR-146a and miR-155 in skin tissue of rats suffering from aGvHD. Analysis of intestinal T cells indicated 23 miRNAs differentially regulated between aGvHD and controls. Two of these miRNAs were differentially expressed either in skin (miR-326) or in intestinal (miR-345-5p) tissue. Comparison of intestinal and peripheral blood T cells indicated common dysregulated expression of miR-99a, miR-223, miR-326, and miR-345-5p. Analysis of predicted gene targets for these miRNAs indicated potential targeting of an inflammatory network both in skin and in the intestines that may further regulate inflammatory cytokine production. In conclusion, comprehensive miRNA profiling in rats suffering from aGvHD demonstrate tissue-specific differences in the expression patterns of miRNA that may not be detected by profiling of peripheral blood T cells alone. These tissue-specific miRNAs may contribute to distinct pathologic mechanisms and could represent potential targets for therapy.
Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo , Oslo , Norway.
Dasaradha
D
Jalapothu
Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
Margherita
M
Boieri
Institute of Cellular Medicine, Medical School, Newcastle University , Newcastle-upon-Tyne , UK.
Rachel E
RE
Crossland
Institute of Cellular and Molecular Immunology, University Medical Center Göttingen , Göttingen , Germany.
Pranali
P
Shah
Department of Immunology, Oslo University Hospital - Rikshospitalet , Oslo , Norway.
Isha A
IA
Butt
Institute of Cellular Medicine, Medical School, Newcastle University , Newcastle-upon-Tyne , UK.
Jean
J
Norden
Institute of Cellular and Molecular Immunology, University Medical Center Göttingen , Göttingen , Germany.
Ralf
R
Dressel
Institute of Cellular Medicine, Medical School, Newcastle University , Newcastle-upon-Tyne , UK.
Anne M
AM
Dickinson
Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Immunology, Oslo University Hospital - Rikshospitalet, Oslo, Norway.
Marit
M
Inngjerdingen
T cells; aGvHD; gut; miRNA; skin
Nature. 2010 Aug 12;466(7308):835-40
20703300
Cell. 2007 Jun 29;129(7):1401-14
17604727
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12481-6
16885212
Cell. 2010 Sep 17;142(6):914-29
20850013
Clin Transplant. 2014 Mar;28(3):314-23
24494749
Immunity. 2012 Aug 24;37(2):339-50
22921121
Cell Cycle. 2011 Dec 15;10 (24):4256-71
22134354
Nature. 2004 Sep 16;431(7006):350-5
15372042
J Clin Invest. 2013 Apr;123(4):1590-604
23454750
Immunity. 2003 Oct;19(4):549-59
14563319
Mol Ther Nucleic Acids. 2014 Sep 23;3:e194
25247240
Exp Hematol. 2016 Jul;44(7):624-634.e1
27013207
J Immunol. 2012 Mar 15;188(6):2499-508
22308308
Gene. 2014 Jul 10;544(2):128-33
24792898
Bone Marrow Transplant. 2013 Jun;48(6):849-53
23222379
Cancer Res. 2008 Jun 15;68(12 ):4525-30
18559496
Science. 2007 Apr 27;316(5824):604-8
17463289
Blood. 2012 May 17;119(20):4786-97
22408260
J Clin Invest. 2015 Jul 1;125(7):2825-40
26098216
Leukemia. 2013 Jul;27(7):1527-37
23399894
J Neurosci. 2009 Dec 2;29(48):15161-8
19955368
Nat Immunol. 2009 Dec;10(12):1252-9
19838199
Cell. 2004 Jan 23;116(2):281-97
14744438
Blood. 2014 Oct 16;124(16):2586-95
25205119
Front Immunol. 2013 Dec 02;4:420
24348483
Nat Rev Immunol. 2010 Feb;10(2):111-22
20098459
Lancet. 2009 May 2;373(9674):1550-61
19282026
Blood. 2015 Sep 10;126(11):1314-23
26138686
J Biol Chem. 2014 Oct 3;289(40):28019-39
25138213
Blood. 2003 Nov 15;102(10 ):3815-21
12842995
Gene Ther. 2011 Dec;18(12):1104-10
21525952
Front Immunol. 2016 Mar 08;7:56
27014257
Annu Rev Immunol. 2007;25:139-70
17129175
Cell Adh Migr. 2010 Apr-Jun;4(2):199-203
20168078
Immunity. 2015 Jul 21;43(1):52-64
26163372